TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
DUBLIN - Investment firm Citadel Group has disclosed a 1.58% ownership position in Mural Oncology plc, according to a regulatory filing published Friday.
The disclosure, made under Irish Takeover Panel rules, reveals Citadel holds interests in 274,914 shares, representing 1.58% of the biopharmaceutical company. This includes 246,914 directly owned shares and 28,000 shares through stock-settled derivatives.
The filing also shows Citadel maintains short positions equivalent to 0.99% of Mural Oncology’s outstanding shares, primarily through stock-settled derivatives including options.
Trading activity detailed in the disclosure indicates Citadel executed multiple transactions on August 14, with purchase prices ranging from $1.76 to $1.84 per share. The firm also reported various options positions with strike prices between $2.50 and $7.50, with expiration dates extending to January 2027.
Mural Oncology, an Irish-based company focused on cancer treatments, trades with the ISIN identifier IE000LK2BOB4. The stock closed at $1.80 on Thursday.
Companies and investment firms are required to disclose positions exceeding 1% in Irish companies that may be involved in potential takeover situations, though the filing does not indicate any current takeover offer for Mural Oncology.
The information was disclosed in a standard Form 8.3 filing submitted to regulatory authorities based on positions held as of August 14.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.